PARATEK PHARMACEUTICALS, INC.

PRTKUnited States

33 filed reports · 402 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$160M

FY2022 · to Dec 31, 2022

up +23.1% vs $130M

10-K

Net income

-$63.6M

FY2022 · to Dec 31, 2022

a year earlier: -$59.1M

10-K

Operating income

-$46.2M

FY2022 · to Dec 31, 2022

a year earlier: -$41.1M

10-K

Latest quarter

Revenue

$40M

Q2 FY2023 · to Jun 30, 2023

up +34.9% vs $29.6M

10-Q

Net income

-$14.6M

Q2 FY2023 · to Jun 30, 2023

a year earlier: -$17.6M

10-Q

Operating income

-$9.41M

Q2 FY2023 · to Jun 30, 2023

a year earlier: -$13.2M

10-Q

Filed reports

33 reports · Jun 2015 to Jun 2023

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR253,212Jun 2015 to Jun 2023
Annual · 10-KSEC EDGAR82,861Dec 2015 to Dec 2022

Documents

PeriodTypePeriod endPublishedFactsSource
FY2023 Q210-Q2023-06-302023-08-03295Open
FY2023 Q110-Q2023-03-312023-05-09168Open
FY202210-K2022-12-312023-03-16483Open
FY2022 Q310-Q2022-09-302022-11-03189Open
FY2022 Q210-Q2022-06-302022-08-03136Open
FY2022 Q110-Q2022-03-312022-05-04127Open
FY202110-K2021-12-312022-03-14363Open
FY2021 Q310-Q2021-09-302021-11-08117Open
FY2021 Q210-Q2021-06-302021-08-09114Open
FY2021 Q110-Q2021-03-312021-05-17113Open
FY202010-K2020-12-312021-03-29327Open
FY2020 Q310-Q2020-09-302020-11-05132Open

Financial data

402 concepts · 6,073 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial397 concepts · 5,953 facts · Dec 2013 to Jun 2023

  • Allocated share based compensation expense48 · Dec 2013 to Jun 2023
  • Cash and cash equivalents at carrying value48 · Dec 2013 to Jun 2023
  • Costs and expenses48 · Dec 2013 to Jun 2023
  • Net income loss48 · Dec 2013 to Jun 2023
  • Operating income loss48 · Dec 2013 to Jun 2023
  • Research and development expense excluding acquired in process cost48 · Dec 2013 to Jun 2023
  • Other nonoperating income expense47 · Mar 2014 to Jun 2023
  • Increase decrease in accounts payable and accrued liabilities46 · Dec 2013 to Jun 2023
  • Share based compensation46 · Dec 2013 to Jun 2023
  • Stockholders equity (US GAAP)45 · Dec 2013 to Jun 2023
  • Common stock par or stated value per share44 · Dec 2014 to Jun 2023
  • Common stock value44 · Dec 2014 to Jun 2023
  • Increase decrease in other operating capital net44 · Dec 2013 to Jun 2023
  • Revenue44 · Dec 2013 to Jun 2023
  • Accounts payable current43 · Dec 2014 to Jun 2023
  • Accrued professional fees current43 · Dec 2014 to Jun 2023
  • Additional paid in capital common stock43 · Dec 2014 to Jun 2023
  • Assets43 · Dec 2014 to Jun 2023
  • Assets current43 · Dec 2014 to Jun 2023
  • Common stock shares authorized43 · Dec 2014 to Jun 2023
  • Common stock shares issued43 · Dec 2014 to Jun 2023
  • Common stock shares outstanding43 · Dec 2014 to Jun 2023
  • Comprehensive income net of tax43 · Dec 2014 to Jun 2023
  • Employee related liabilities current43 · Dec 2014 to Jun 2023

Product1 concept · 83 facts · Mar 2018 to Jun 2023

  • Revenue83 · Mar 2018 to Jun 2023

Geography4 concepts · 37 facts · Dec 2015 to Dec 2021

  • Operating Lease Expiry Period24 · Dec 2015 to Dec 2021
  • Operating Lease Monthly Rent Expenses11 · Dec 2015 to Dec 2020
  • Property plant and equipment additions1 · Mar 2017
  • Property plant and equipment disposals1 · Mar 2017

Segments

120 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or service4 members · 83 facts

  • Collaboration and Royalty Revenue [Member]27 · Mar 2018 to Jun 2023
  • Product Revenue, Net [Member]22 · Mar 2019 to Jun 2023
  • Government Contract Grant Revenue [Member]17 · Mar 2020 to Jun 2023
  • Government Contract Service Revenue [Member]17 · Mar 2020 to Jun 2023

Statement geographicalus-gaap:StatementGeographicalAxis3 members · 20 facts

  • Boston [Member]10 · Dec 2015 to Mar 2018
  • King of Prussia [Member]8 · Dec 2015 to Mar 2018
  • King of Prussia and Boston [Member]2 · Mar 2017

Statement geographicalsrt:StatementGeographicalAxis2 members · 17 facts

  • Boston [Member]11 · Dec 2018 to Dec 2021
  • King of Prussia [Member]6 · Dec 2018 to Dec 2021

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of PARATEK PHARMACEUTICALS, INC. (PRTK) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

PARATEK PHARMACEUTICALS, INC. (PRTK): FY2022 revenue $160M · FactIQ